Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)

Exclusion Criteria

• •1. Having received an investigational product within 2 months of Screening Visit.
• •2. Inability to comply with study procedures or with study treatment intake.
• •3. Any significant lung disease which is considered by the investigator to be clinically significant.
• •4. Patients who suffer from Chronic Obstructive Pulmonary Disease (COPD)
• •5. Previous or current smokers who have a smoking history greater than 5 pack years.
• •6. Patients with any uncontrolled disease that might, in the judgment of the investigator, place the patients at undue risk or potentially compromise the results or interpretation of the study.
• •7. Patients with QTc \>450msec at the Screening Visit.
• •8. Patients with serum potassium \<3.5 mEq/L or \>6 mEq/L.
• •9. Intolerance/hypersensitivity or any contra-indication to treatment with beta2-agonists and/or inhaled corticosteroids.
• •10. Patients who have a history of alcohol or substance abuse that in the opinion of the Investigator may be of clinical significance.
• •11. Patients who have undergone major surgery in the previous 3 months.
• •12. Patients who have had an exacerbation of asthma, requiring treatment with oral steroids during the last month prior to Screening Visit.
• •13. Patients treated with slow-release corticosteroids 2 months prior to Screening Visit.
• •14. Patients currently treated with anti-IgE Antibodies.
• •15. Patients who have had a respiratory tract infection within 4-weeks prior to Screening Visit.
• •16. Females not willing to use effective contraceptive measures such as oral contraceptive or intra-uterine device (IUD).
• •17. Females who are pregnant, lactating or planning to become pregnant